New Huntington's drug enters first human tests
NCT ID NCT07246941
First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 4 times
Summary
This early-stage study tests a new drug called RG6496 in people who carry the gene for Huntington's disease. The main goal is to check if the drug is safe and how the body handles it. About 40 participants will receive a single dose injected into the spine, with some getting a placebo. The study has two parts: an initial blinded phase and an open-label extension where everyone gets the drug.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUNTINGTON'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cambridge Centre for Brain Repair
Cambridge, Cambridgeshire, CB2 0PY, United Kingdom
-
Hospital Britanico de Buenos Aires
Ciudad Autonoma Bs As, C1280AEB, Argentina
-
Monash Health
Clayton, Victoria, 3168, Australia
-
Montreal Neurological Institute Clinical Research Unit
Montral, Quebec, H3A 2B4, Canada
-
New Zealand Brain Research Institute
Christchurch, 8011, New Zealand
-
Royal Melbourne Hospital
Parkville, Victoria, 3050, Australia
-
Westmead Hospital
Westmead, New South Wales, 2145, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Brain scan tracer could reveal hidden signs of psychosis in Parkinson's
- Hope for Huntington's: new drug aims to slow decline in major trial
- New hope for Huntington's patients: drug eases involuntary movements
- Experimental drug aims to curb disinhibition in dementia patients
- New drug SRP-1005 takes first step against Huntington's
- Can video games help Huntington's patients move and think better?